Hello, everyone. Welcome to the 2022 J.P. Morgan Healthcare Conference. I'm Lingling Chen from China Healthcare Investment Banking team, and today we're very honored to have Dr. Jingwu Zang from I-Mab Biopharma to present at our conference. I-Mab is a biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics. Since its establishment, I-Mab has experienced tremendous growth and has developed an innovative pipeline of over 10 preclinical and clinical-stage assets. The company has also been listed on the Nasdaq since January 2020. Our speaker today, Dr. Jingwu Zang, is the founder and chairman of the company, with over 30 years of experience in academia and industry. Now I'll pass the stage on to Dr. Zang for the presentation. Thank you. Hi, I'm Jingwu Zang, Founder, Chairman, and Acting CEO of I-Mab. First of all, I'd like to thank you all for joining this virtual meeting today. This is a great opportunity for me to introduce I-Mab and report to you the remarkable progress that we have made in 2021 and the exciting outlook for 2022. Now on slide three, I-Mab is focused on discovery, development, manufacturing, and soon commercialization of innovative biologics of first-in-class, best-in-class potential in the therapeutic area of immuno-oncology. There are really four highlighted aspects to best describe I-Mab. First, our innovation is global and innovation is our differentiation. I-Mab has always been focused on innovative biologics or first-in-class, best-in-class potential in the therapeutic area of immuno-oncology because our R&D strength is in immuno-oncology. Our innovation is best represented by novel or highly differentiated monoclonal antibodies, bispecific antibodies, and recently by technology-enabled super antibodies. For example, lemzoparlimab and uliledlimab are among the global frontrunners and differentiated from competitive compounds. I will elaborate further in this presentation. Second, our pipeline is global, and it is not only innovative, but also advanced. It is comprised of 20 clinical and pre-clinical assets. Seven clinical assets are being evaluated in 15 phase II or phase III clinical trials in U.S. and China, including four registrational trials in 2022. Third, our business is global. Over the years, we have established more than 20 business partnerships, including in-licensing, out-licensing, and co-development. Through out-licensing, we have generated a revenue stream of $1 billion in cash to be realized through 2025 via upfront payments and milestone payments. These large transactions have further validated the innovative nature and the value of I-Mab's assets. Fourth, our ambition is to become a global biopharma with a global R&D and a manufacturing and commercialization capabilities. We started as a discovery company in 2016 and are now global clinical-stage biotech. We're well underway to become a global biopharma in a few years. Now on slide three, I-Mab's pipeline is designed to address the current unmet medical needs in the oncology therapeutic area. That is, the majority of the cancer patients do not or poorly respond to PD-1, PD-L1 therapies. As you can see on this slide, if ORR 30% is used as a cutoff, the majority of cancer patients fall below this 30% response line. These cancer patients seem to have a so-called immunosuppressive cold tumors that respond poorly to immunotherapies. Therefore, there's a huge unmet medical need for new therapies that can overcome tumor resistance to the immunotherapy. On slide five, at I-Mab, we rely on our immunology expertise and drug development experience to design and develop monoclonal and bispecific therapeutic antibodies capable of mobilizing or activating the immune network to fight against cancers or turning cold tumors to hot tumors for better treatment effect. These novel highly differentiated antibodies are now in various stages of clinical trials. On slide six, I-Mab's innovation comes in three waves. The first wave is represented by highly differentiated monoclonal antibodies such as lemzoparlimab, CD47 antibody, uliledlimab, CD73 antibody, and others. They are currently in phase II clinical trials globally. The second wave is comprised of novel bispecific antibodies. The most advanced are in phase I clinical trials, and they are followed by the third wave, even more innovative assets that are enabled only by transformative technologies such as mRNA technology, cell-penetrating antibody technology, locally activated Probody technology, and AI protein design technology. They represent the most innovative antibodies that are only enabled by cutting-edge technologies. On slide number seven, our current pipeline is comprised of 10 clinical stage assets that are either novel or highly differentiated, including monoclonal antibodies and bispecific antibodies. Now, there are two important features about this pipeline. The first feature is about innovative nature of the pipeline. As you can see, the pipeline is very innovative with lemzoparlimab CD47 antibody and uliledlimab CD73 antibody being global front runners and highly differentiated from the competitor compounds. In 2022, we will have critical data readouts for both assets, and we are very excited about that. We aim to move forward with lemzoparlimab, potentially to start two registrational trials in China in 2022. Other clinical assets such as TJ107, our long-acting interleukin-7 and novel itumab B7-H3 monoclonal antibody, have also come to play in phase II or proof of concept clinical trials. Further, CSF1R receptor antibody and bispecific antibodies are now in clinical trials as newcomers. There are more to come in 2022, 2023 from the current pool of innovative, preclinical stage assets. Now, the other feature is that this pipeline is quite advanced. Among 20 clinical programs that are ongoing or start soon, 15 are phase II or phase III clinical trials, including four registrational trials for felzartamab, and potentially lemzoparlimab by the end of 2022. The pipeline is well-positioned with three key assets, including the two hematologic malignancy assets in registrational trials in 2022. Five key assets in phase II are proof of concept clinical trials and three assets in early stage clinical trials. We're very excited about the potential of this innovative pipeline. Now, there are two examples on slide 8. The first example is lemzoparlimab CD47 antibody. The molecule is differentiated by design to avoid binding to regular cells while maintain strong anti-tumor activity. This molecular differentiation translates to clinical advantages that are being validated. Over 100 patients have been treated so far with lemzoparlimab. We have seen some of the clinical advantages when lemzoparlimab is administered without the need of a priming dose in terms of clinical safety, without hemolytic anemia, no cytokine effects, and promising anti-tumor activity in multiple clinical trials so far. On slide number 9, we're running three clinical programs with lemzoparlimab for non-Hodgkin's lymphoma, AML, MDS, and solid tumors. Our global partner, AbbVie, is running two clinical programs globally. As I mentioned earlier, based on the clinical data being generated. We hope to start two registrational trials in MDS and non-Hodgkin's lymphoma in 2022. Our ambition, of course, is to get the lemzoparlimab registered as the first CD47 antibody in China, and work together with AbbVie to facilitate global registration. On slide number 10, uliledlimab is another example. It is also among the global frontrunners with its own differentiation. The molecule is differentiated by design to recognize a unique epitope that is not associated with a hook effect to avoid an abnormal PK/PD relationship. Our initial clinical results are very promising in terms of safety, PK/PD, and early efficacy signals. We have determined RP2D and are running in parallel two clinical trials for solid tumors in both U.S. and China. There will be a data readout events in 2022, and we are looking forward to that. On slide number 11, in 2021, we have made remarkable progress in pipeline development. We have achieved 21 key clinical milestones, including successful completion of third-line registrational trial for felzartamab ready for BLA submission. We also achieved a number of BD milestones. These achievements have set a very strong foundation for 2022. 2022 will be an even more exciting year in terms of pipeline development. On slide number twelve, as I mentioned earlier, our pipeline is quite advanced with felzartamab and lemzoparlimab for hematologic oncology, progressing towards registration. We're positioning the two hematologic oncology key assets for commercialization that will take place in the near term. Our strategy is to position lemzoparlimab and felzartamab in combination with other treatment agents to cover the three major hematologic malignancy indications, including multiple myeloma, leukemia, AML, MDS, and lymphoma as a second treatment option and potentially first-line treatment options. In parallel, we're in the process of building our core commercialization team under the leadership of Mr. Zhu in sync with a product registration partner. On slide 13, just a few more words on the corporate side of things. We have achieved over 20 global and domestic business partnerships and transactions. This includes in-licensing, out-licensing, co-development deals. The most notable deals are lemzoparlimab deals with AbbVie for $1.94 billion in 2021, and lemzoparlimab deal with Junshi for $350 million in 2022. These deals have further validated I-Mab's capability as a global innovative biotech, and have generated a cash stream of around $1 billion to be realized through 2025. Which is quite unique for a clinical stage biotech. We will continue executing more similar deals as we promised to the market. On slide number 14, in terms of capital market listings, I-Mab was listed on Nasdaq in January 2020. We recently announced that we will prioritize and accelerate our Hong Kong Stock Exchange dual listing process to provide more flexibility to our investors, especially the international investors. We hope to complete the listing in 2022, and we will report our progress as we move forward. On slide number 15, as a global biotech, we have built our global footprint in U.S. and China. Our headquarters is in Shanghai with R&D facilities or sites in multiple cities in U.S. and China. Our manufacturing facility is being built in Hangzhou. We're building a new R&D center in San Diego, which will open in early 2022. In addition, our commercialization capability is also being built to prepare for our first product launch in 2023. On slide 16, I-Mab has emerged rapidly as a discovery startup in 2016. We are now a global clinical stage biotech with an innovative and advanced pipeline of 20 clinical and pre-clinical assets moving towards registration. We have generated a revenue stream of $1 billion in cash to be realized through 2025. We're now well underway to become a global biopharma with manufacturing and commercialization capabilities in 2024. We're growing at a very fast pace, and we're very excited and I take a pride of what we have achieved so far. Now, on slide 17, I just want to say 2022 is an even more exciting year for I-Mab. We are set to achieve a series of high impact and value generating milestones or catalysts. We will strive to achieve 20 clinical milestones, including start of registrational trials for lemzoparlimab, critical data readouts and our clinical trial starts. As a result, our pipeline will have advanced to include four registrational trials, 11 phase II clinical trials, three phase I clinical trials, and 7-10 preclinical programs by the end of 2022. In addition, we will deliver the key corporate milestones, including the BD deals that we have been working on. As always, we will strive to deliver what we promise to create value for the company and our shareholders. Thank you for your attention, and have a great day.